Posted by Michael Wonder on 13 Feb 2025
FDA grants fast track designation to PleoPharma's investigational new drug PP-01 for the mitigation of cannabis withdrawal symptoms in patients with cannabis use disorder: a potential first in class treatment
13 February 2025 - Phase 3 preparations underway.
PleoPharma announced today that the US FDA has granted fast track designation to PP-01, its lead asset, for the mitigation of cannabis withdrawal syndrome in patients with cannabis use disorder.
